PRESSRELEASES

6 December, 2022

Nanexa has started the Phase 1 study of NEX-20 according to plan

Nanexa AB (publ) today announced that the first dose of NEX-20 has been administrated in the Phase 1 study NEX-20-01.

READ MORE

16 November, 2022

Nanexa AB and VitriVax, Inc. have resolved the patent infringement lawsuit

Nanexa AB and VitriVax, Inc. jointly announce that they have resolved the patent infringement lawsuit filed by Nanexa AB against VitriVax, Inc. in the United States District Court for the District of Delaware.

READ MORE

LATEST REPORTS

PRESENTATIONS

2022-09-15

Webcast med kommentar och Q&A avseende start av projekt NEX-22 – Vd David Westberg och styrelseordförande Göran Ando svarar på frågor från analytiker och tittare.

2022-08-26

Webcast med Rapportkommentar, Delårsrapport jan-jun 2022.

2022-05-19

ABGSC Life Science Summit

MEET NANEXA

Inga planerade träffar

PRENUMERERA